Non-Small Cell Lung Cancer (NSCLC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
Non-Small Cell
Lung Cancer (NSCLC) Market Outlook
Thelansis’s “Non-Small Cell Lung
Cancer (NSCLC) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2026 To 2036” covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Non-Small Cell
Lung Cancer (NSCLC) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Non-Small Cell
Lung Cancer (NSCLC) Overview
Non-small cell lung cancer (NSCLC) is
the predominant form of lung cancer, accounting for approximately 85% of all
cases. Around 15–20% are diagnosed at an early stage, where surgical resection,
often combined with adjuvant chemotherapy or radiotherapy, offers the best
chance of cure. Risk factors can be divided into modifiable and non‑modifiable
categories. Modifiable risks include tobacco smoking, secondhand smoke, and
occupational or environmental exposures such as asbestos, radon, arsenic,
chromium, nickel, ionizing radiation, and polycyclic aromatic hydrocarbons. Non‑modifiable
risks include age, family history, and genetic predisposition. Additionally,
prior chest irradiation for malignancies such as breast cancer or Hodgkin
lymphoma increases the likelihood of developing NSCLC later in life.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by robust research, including:
- In-depth interviews with leading KOLs
and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based
automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets
and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the most
promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment